title: [Triplets therapy for the patients of multiple myeloma].
abstract: The treatment of multiple myeloma has undergone profound changes due to the use of novel agents, such as the immunomodulatory drugs(IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib, combined with conventional chemotherapy. Data from phase III randomized trials support the use of a combination consisting of bortezomib plus dexamethasone plus an IMiD or alkylator or anthracycline. Although treatment with new drugs is now common, and the 3-drug combinations seem more effective than 2-drug combinations, there are few randomized trials that have compared modern combinations with each other. This article reviews the current data on the most commonly used and tested triplet combinations for the treatment of newly diagnosed multiple myeloma.
authors.affiliation: Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine.
authors.forename: Tadao
authors.initials: T
authors.lastname: Ishida
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000628:therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D011480:Protease Inhibitors